Botulinum toxin

Handbook of Toxicology of Chemical Warfare Agents

Volumn , Issue , 2009, Pages 407-432

  Anderson, Jaime ^a   Williams, Patrick T ^a   Katos, Alexandre M ^a   Krasna, Mark ^b   Burrows, Whitney ^c,d   Hilmas, Corey J ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b Cancer Center at St Joseph Medical Center   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876158481     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374484-5.00030-4     Document Type: Chapter

References (143)

1. Adler M., MacDonald D.A., Sellin L.C., Parker G.W. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon 1996, 34:237-249.
2. Arnon S. Botulism as an intestinal toxemia. Infections of the Gastrointestinal Tract 1995, 257-271. Raven Press, New York. M. Blaser, P. Smith, J. Ravdin, H. Greenberg, R. Guerrant (Eds.).
3. Arnon S.S. Infant botulism. Textbook of Pediatric Infections of the Gastrointestinal Tract 1998, W.B. Saunders, Philadelphia. R.D. Feigen, J.D. Cherry (Eds.).
4. Arnon S., Schecter R., Inglesby T., Henderson D., Bartlett J., Ascher M., Eitzen E., Fine A., Hauer J., Layton M., Lillibridge S., Osterholm M., O'Toole T., Parker G., Perl T., Russell P., Swerdlow D., Tonat K. Botulinum toxin as a biological weapon. Medical and Public Health Management. JAMA 2001, 285:1059-1070.
5. Bakry N., Kamata Y., Simpson L. Expression of botulinum toxin binding sites in Xenopus oocytes. Infect. Immun 1997, 65:2225-2232.
6. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucl. Acids Res. 2000, 28:235-242.
7. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell Biol. 1986, 103:535-544.
8. Blanes-Mira C., Merino J.M., Valera E., Fernandez-Ballester G., Gutiérrez L.M., Viniegra S., Pérez-Payá E., Ferrer-Montiel A. Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis. J. Neurochem 2004, 88:124-135.
9. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., DeCamilli P., SudoffT.C., Niemann H., Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365:160-163.
10. Brackett D.W. Holy Terror Armageddon in Tokyo 1996, Weatherhill, New York, NY.
11. Brunger A.T., Briedenbach M.A., Jin R., Fischer A., Santos J.S., Montal M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLOS Path 2007, 3:1191-1194.
12. Cai S., Sarkar H.K., Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 1999, 38:6903-6910.
13. Ò): pharmacology and biochemistry. Clin. Dermatol 2004, 22:23-28.
14. Cardella M., Jemski J., Tonik E., Fiock M. Resistance of guinea pigs immunized with botulinum toxoids to aerogenic challenge with toxin. US Army Biological Laboratories Report Test No. 60-TE-1323 1963, DTIC AD0404870.
15. CDC (Centers for Disease Control and Prevention) Foodborne botulism -Oklahoma, 1994. Morb. Mortl. Wkly Rep 1995, 44:200-202.
16. CDC (1998). Botulism in the United States, 1899-1996. In Handbook for Epidemiologists, Clinicians, and Laboratory Workers. US Department of Health and Human Services.
17. CDC Outbreak of gastroenteritis associated with an interactive water fountain at a beachside park -Florida. MMWR Morb. Mortal. Wkly Rep 1999, 49:565-568.
18. Chen F., Kuziemko G., Stevens R. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun 1998, 66:2420-2425.
19. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998, 21:701-710.
20. Chia J.K., Clark J.B., Ryan C.A., Pollack M. Botulism in an adult associated with foodborne intestinal infection with. Clostridium botulinum. N. Engl. J. Med 1986, 315:239-241.
21. Cicarelli A., Whaley D., McCroskey L., Gimenez D., Dowel V., Hatheway C. Cultural and physiological characteristics of Clostridium botulinum type G and the susceptibility of certain animals to its toxin. Appl. Environ. Microbiol. 1977, 34:843-848.
22. CIDRAP (Center for Infectious Disease Research and Policy) (2004) Reports blame Florida botulism cases on misused toxin. Twin Cities, Minn December 15, 2004, University of Minnesota, CIDRAP.
23. Coffield J., Bakry N., Zhang R., Carlson J., Gomella L., Simpson L. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J. Pharmacol. Exp. Ther 1997, 280:1489-1498.
24. Coleman I. Studies on the oral toxicity of Clostridium botulinum toxin, type A. Can J. Biochem. Physiol 1954, 32:27-34.
25. Couteaux R. Motor end plate structure. The Structure and Function of Muscle 1973, 486-514. Academic Press, New York. G.H. Bourne (Ed.).
26. Cox N., Hinkle R. Infant botulism. Am. Fam. Phys. 2002, 65:1388-1392.
27. Dack G., Wood W. Serum therapy of botulism in monkeys. J. Infect. Dis 1928, 42:209-212.
28. Daniels-Holgate P., Dolly J. Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J. Neurosci. Res. 1996, 44:263-271.
29. Dembeck Z.F. Modeling for bioterrorism incidents. Biological Weapons Defense: Infectious Disease and Counterbioterrorism 2005, 23-40. Humana Press, Totowa, NJ. L.E. Linder, F.J. Lebeda, G.W. Korch (Eds.).
30. Dolman C., Murakami L. Clostridium botulinum type F with recent observations on other types. J. Infect. Dis 1961, 109:107-129.
31. Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A., Chapman E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 2003, 162:1293-1303.
32. Eleopra R., Tugnoli V., Quatrale R., Rossetto O., Montecucco C. Different types of botulinum toxin in humans. Mov. Disord 2004, 19:S53-S59.
33. Erbguth F.J. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov. Disord. 2004, 19(S8):S2-S6.
34. Erdal E., Bartels F., Binscheck T., Erdmann G., Frevert J., Kistner A., Weller U., Wever J., Bigalke H. Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells. Naunyn Schmiedebergs Arch. Pharmacol 1995, 351:67-78.
35. Fernández-Salas E., Steward L.E., Ho H., Garay P.E., Sun S.W., Gilmore M.A., Ordas J.V., Wang J., Francis J., Aoki K.R. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl Acad. Sci. USA 2004, 101:3208-3213.
36. Franz D.R. Defense against toxin weapons. Medical Aspects of Chemical and Biological Weapons (Textbook of Military Medicine series, Warfare, Weaponry, and the Casualty, Part I 1997, 603-619. Borden Institute, Washington, DC. 1st edition. R. Zajtchuk (Ed.).
37. Fujinaga Y., Inoue K., Watanabe S., Yokota K., Hirai Y., Nagamachi E., Oguma K. The haemagglutinin of Clostridium botulinum type C progrenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology 1997, 143:3841-3847.
38. Garcia-Rodriguez C., Levy R., Arndt J.W., Forsyth C.M., Razai A., Lou J., Geren I., Stevens R.C., Marks J.D. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol 2007, 25:107-116.
39. Gelzleichter, T., Myers, M., Menton, R., Niemuth, N., Matthews, M. (1998a). Correlation of toxicity of botulinum toxins by different routes of administration. Battelle Final Report TASK 97-51.
40. Gelzleichter, T., Myers, M., Menton, R., Niemuth, N., Matthews, M. (1998b). Evaluation of the passive protection against five serotypes of botulinum toxin provided by botulinum human immune globulin in an animal model. Battelle Final Report Task 96-45.
41. Gelzleichter T., Myers M., Menton R., Niemuth N., Matthews M. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J. Appl. Toxicol 1999, 19:35-38.
42. Giminez D.F., Cicarelli A.S. Another type of Clostridium botulinum. Zentralbl. Bakteriol. Orig. A] 1970, 215:221-224.
43. Habermann E., Dreyer F. Clostridial neurotoxins: handling and action at the cellular and molecular level. Curr. Top. Microbiol. Immunol 1986, 129:93-179.
44. Hall J.D., McCroskey L.M., Pincomb B.J., Hatheway C.L. Isolation of an organism resembling Clostridium baratii which produces type F botulinal toxin from an infant with botulism. J. Clin. Microbiol. 1985, 21:654-655.
45. Halouzka J., Hubalek Z. Effect of pH on the stability of type-C toxin of. Clostridium botulinum. Folia Microbiol. (Praha) 1992, 37:157-158.
46. Hatheway C.L. Laboratory Diagnosis of Infectious Diseases: Principles and Practice. Botulism 1988, Vol. I:111-133. Springer-Verlag, Berlin. A. Balows, W.J. Hausler, M. Ohashi (Eds.).
47. Hatheway C.H., Snyder J.D., Seals J.E., Edell T.A., Lewis G.E. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J. Infect. Dis 1984, 150:407-412.
48. Heckly R., Hildebrand G., Lamanna C. On the size of the toxic particle passing the intestinal barrier in botulism. J. Exp. Med 1960, 111:745-779.
49. Hilmas, C.J., Deshpande, S.S, Adler, M. (2006a). Evaluation of an appropriate animal model involving mouse, guinea pig, rat, and rabbit muscle for testing future therapeutics against botulinum neurotoxin (BoNT): a comparative study of skeletal muscle sensitivity to BoNT serotypes A, B, and E. National Biodefense Analysis and Countermeasures Center (NBACC) Technical Report.
50. Hilmas, C.J., Deshpande, S.S., Keller, J.E., Williams, P.T. (2006b). Evaluation of stability of botulinum toxins in biological fluids and liquid media. Bioscience Review, US Army Medical Research Institute of Chemical Defense.
51. Holzer, V.E. (1962). Botulism from inhalation. Med. Klin. 57: 1735-8. (Translation: original document in German).
52. House, M., Cresthull, P., Crook, J., Obserst, F. (1964). Changes in concentration of botulinum toxin in dog serum after parenteral administration. Chemical Research and Development Labs Edgewood Arsenal Report (CRDLR) 3229; DTIC AD0451095.
53. Iakovlev A. The importance of antitoxic immunity for the defence of the body in respiratory penetration by bacterial toxins. I. Role of passive immunity in the defence of the body against respiratory disease caused by Clostridium botulinum toxins. J. Microbiol. Epidemiol. Immunobiol. 1958, 29:904-909.
54. Iida H., Ono T., Karashimada T. Experimental studies on the serum therapy of type E botulism: the relationship between the amount of toxin in the blood and the effect of antitoxic serum. Jpn. J. Med. Sci. Biol. 1970, 23:344-347.
55. Jankovic J., Brin M.F. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve (Suppl 1997, 6):S129-S145.
56. Jemski, J. (1960). Recoveries and guinea pig LD50s of aerosols of botulinum toxins disseminated by the Hartman Fixture at 75°F and 50 percent relative humidity. Fort Detrick Applied Aerobiology Division -Technical Evaluation Report Test No. 60-TE-1274; DTIC AD0497593.
57. Jemski, J. (1961a). Aerosol challenge of guinea pigs, parenterally immunized with botulinum toxoid, with type D botulinum toxin disseminated by the Hartman fixture at 75°F and 50 percent relative humidity. Fort Detrick Applied Aerobiology Division -Technical Evaluation Report Test No. 61-TE-1396; DTIC AD0497611.
58. Jemski, J. (1961b). Challenge of parenterally immunized guinea pigs with aerosols of botulinum toxins disseminated by the Hartman fixture at 75°F and 50% relative humidity. Fort Detrick Applied Aerobiology Division -Technical Evaluation Report Test No. 60-TE-1323. DTIC AD0497563.
59. Jin R., Rummel A., Binz T., Brunger A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006, 444:1092-1095.
60. Kalb S.R., Goodnough M.C., Malizio C.J., Prikle J.L., Barr J.R. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics. Anal. Chem. 2005, 77:6140-6146.
61. Kauffman J., Way J., Siegel L., Sellin L. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol. Appl. Pharmacol 1985, 79:211-217.
62. Keller J.E., Neale E.A. The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. 2001, 276:13476-13482.
63. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999, 456:137-142.
64. Koenig M., Spickard A., Cardella M., Rogers D. Clinical and laboratory observations on type E botulism in man. Medicine (Balt.) 1964, 43:517-545.
65. Koriazova L.K., Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 2003, 10:13-18.
66. Lalli G., Herreros J., Osborne S.L., Montecucco C., Rosetto O., Schiavo G. Functional characterization of tetanus and botulinum neurotoxins binding domains. J. Cell Sci. 1999, 112:2715-2724.
67. Lamanna C. The most poisonous poison. Science 1959, 130:763-772.
68. Lamanna C. Immunological aspects of airborne infection: some general considerations of response to inhalation of toxins. Bacteriol. Rev. 1961, 25:323-330.
69. Lamanna C., Meyers C. Influence of ingested foods on the oral toxicity in mice of crystalline botulinal type A toxin. J. Bacteriol 1959, 79:406-410.
70. Lecour H., Ramos H., Almeida B., Barbosa R. Foodborne botulism: a review of 13 outbreaks. Arch. Intern. Med 1988, 148:578-580.
71. Lewis G., Metzger J. Studies on the prophylaxis and treatment of botulism. Natural Toxins 1980, 601-606. Pergamon Press, New York. D. Baker, T. Wadstrom (Eds.).
72. Lewis J.C., Smith G.R., White V.J. An outbreak of botulinum in captive hamadryas baboons. Vet. Rec 1990, 126:216-217.
73. Lindstrom M., Nevas N., Kurki J., Sauna-aho R., Latvala-Kiesila A., Polonen I., Korkeala H. Type C botulism due to toxic feed affecting 52,000 farmed foxes and minks in Finland. J. Clin. Microbiol. 2004, 42:4718-4725.
74. MacDonald K.L., Rutherford G.W., Friedman S.M., Dietz J.R., Kaye B.R., McKinley G.F., Tenney J.H., Cohen M.L. Botulism and botulism-like illness in chronic drug abusers. Ann. Intern. Med 1985, 102:616-618.
75. Mackle I., Halcomb E., Parr M. Severe adult botulism. Anaesth. Intensive Care 2001, 29:297-300.
76. Maksymowych A., Simpson L. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem. 1998, 272:21950-21957.
77. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J 2004, 23:539-552.
78. Maselli R. Pathogenesis of human botulism. Ann. NY Acad. Sci. 1998, 841:122-129.
79. Matveev K. Effect of sublethal doses of botulinal toxin on the organism following multiple administrations. Zhurnal Mikrobiologii 1959, 30:71-80.
80. McCroskey L.M., Hatheway C.L. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J. Clin. Microbiol. 1988, 26:1052-1054.
81. McLellan K., Das R.E., Ekong T.A., Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996, 34:975-985.
82. Merson M.H., Dowell V.R. Epidemiologic, clinical and laboratory aspects of wound botulism. N. Engl. J. Med 1973, 289:1105-1110.
83. Meyer K., Eddie B. Perspectives concerning botulism. Zeitschr. F. Hyg 1951, 133:255-263.
84. Middlebrook, J., Franz, D. (2000). Botulism toxins. In Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, pp. 643-54. Virtual Naval Hospital.
85. Midura T.F., Nygaard G.S., Wood R.M., Bodily H.L. Clostridium botulinum type F: isolation from venison jerky. Appl. Microbiol. 1972, 24:165-167.
86. Minervin S., Morgunov I. Multiple properties of C1 botulinum toxin. Zh. Mikrobiol. Epidemiol. Immunobiol. 1941, 10:71-73.
87. Miyazaki S., Sakaguchi G. Experimental botulism in chickens: the caecum as the site of production and absorption of botulinum toxin. Jpn. J. Med. Sci. Biol. 1978, 31:1-15.
88. Moeller R., Puschner B., Walker R., Rocke T., Galey F., Cullor J., Ardans A. Determination of the median toxic dose of type C. botulinum toxin in lactating dairy cows. J. Vet. Diagn. Invest 2003, 15:523-526.
89. Montecucco C., Papini E., Schiavo G. Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett. 1994, 346:92-98.
90. Morton, H. (1961). The toxicity of Clostridium botulinum type A toxin for various species of animals, including man. Armed Services Technical Information Agency. ICR Contract Report: 1-29.
91. Muller V., Scheibel I. Preliminary report on the isolation of an apparently new type of. Clostridium botulinum. Acta Pathol. Microbiol. Scand 1960, 48:80.
92. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sato K., Sekiguchi M., Takahashi M., Kozaki S. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 1996, 378:253-257.
93. Oberst F., Crook J., Cresthull P., House M..Evaluation of botulinum antitoxin, supportive therapy, and artificial respiration in monkeys with experimental botulism. Clin. Pharmacol. Ther 1967, 9:209-214.
94. Ohishi I. Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect. Immun 1984, 43:487-490.
95. Ohishi I., Sugii S., Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect. Immun 1977, 16:107-109.
96. Ono T., Karashimada T., Iida H. Studies on the serum therapy of type E botulism (Part III). Jpn. J. Med. Sci. Biol. 1970, 23:177-191.
97. Pak Z., Bulatova T. Distribution of a tracer preparation with botulinal toxin in the organism of white mice. Farmakologiya I Toksikologiya 1962, 25:478-482.
98. Palm P., McNerney J., Hatch T. Respiratory dust retention in small animals. AMA Arch. Ind. Health 1956, 13:355-365.
99. Park J.B., Simpson L.L. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect. Immun. 2003, 71:1147-1154.
100. Richardson W.H., Frei S.S., Williams S.R. A case of type F botulism in southern California. J. Toxicol. Clin. Toxicol 2004, 42:383-387.
101. Robinson R.F., Nahata M.C. Management of botulism. Ann. Pharmacother 2003, 37:127-131.
102. Sakaguchi G., Sakaguchi S. Oral toxicities of Clostridium botulinum type E toxins of different forms. Jpn. J. Med. Sci. Biol. 1974, 27:241-244.
103. Sandrock C.E., Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest 2001, 120:562-566.
104. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267:23479-23483.
105. Schiavo, G., Rossetto, O., Catsicas, S., Polverino de Laureto, P., DasGupta, B.R., Benfenati, F., Montecucco, C. (1993a). Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 268: 23784-7.
106. Schiavo, G., Shone, C.C., Rossetto, O., Alexander, F.C., Montecucco, C. (1993b). Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/Synaptobrevin. J. Biol. Chem. 268: 11516-19.
107. Schiavo G., Malizio C., Trimble W.S., Polverino de Laureto P., Milan G., Sugiyama H., Johnson E.A., Montecucco C. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J. Biol. Chem. 1994, 269:20213-20216.
108. Schiavo G., Rosetto O., Tonello F., Montecucco C. Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Curr. Top. Microbiol. Immunol 1995, 195:257-274.
109. Schlesinger R. Deposition and clearance of inhaled particles. Concepts in Inhalation Toxicology 1989, Hemisphere Publishing Corporation, New York. 2nd edition. R.O. McClellan, R.F. Henderson (Eds.).
110. Schmidt J.J., Bostian K.A. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J. Protein Chem. 1997, 16:19-26.
111. Schocken-Iturrino R.P., Avila F.A., Berchielli S.C., Filho A.N. First case of type A botulism in zebu (Bos indicus). Vet. Rec 1990, 126:217-218.
112. Sellin L.C. The pharmacological mechanism of botulism. TIPS 1985, 6:80-82.
113. Sergeyeva T. Detection of botulinal toxin and type A microbe in the organism of sick animals and in the organs of cadavers. Zh. Mikrobiol. 1962, 33:96-102.
114. Sergeyeva T. Detection of type E botulin toxin in an organism. Zh. Mikrobiol. 1966, 4:54-59.
115. Shapiro R.L., Hatheway C., Swerdlow D.L. Botulism in the United States: a clinical and epidemiological review. Ann. Intern. Med 1998, 38:221-228.
116. Sharma S.K., Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 2004, 43:4791-4798.
117. Simpson L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33:155-188.
118. Simpson L.L. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu. Rev. Pharmacol. Toxicol 1986, 26:427-453.
119. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol 2004, 44:167-193.
120. Smart J.L., Roberts T.A., McCullagh K.G., Lucke V.M., Pearson H. An outbreak of type C botulism in captive monkeys. Vet. Rec. 1980, 107:445-446.
121. Smith G. Individual variation in botulism. Br. J. Exp. Pathol 1986, 67:617-621.
122. Smith G.R., Brambell M.R., Gaynor W.T., Greed G.R., de Meurichy W. Botulism in zoological collections. Vet. Rec 1985, 117:534.
123. Smith L., Davis J., Libke K. Experimentally induced botulism in weanling pigs. Am. J. Vet. Res. 1971, 32:1327-1330.
124. Sobel J., Tucker N., Sulka A., McLaughlin J., Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg. Infect. Dis 2004, 10:1606-1611.
125. Sonnabend O., Sonnabend W., Heinzle R., Sigrisf T., Dirnhofer R., Krech U. Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of 5 sudden unexpected deaths. J. Infect. Dis 1981, 143:22-27.
126. Spika J.S., Shaffer N., Hargrett-Bean N., Collin D.S., MacDonald K.L., Blake P.A. Risk factors for infant botulism in the United States. Am. J. Dis. Child 1989, 143:828-832.
127. Stookey, J., Streett, C., Ford D. (1965). Preliminary studies on the disappearance of botulinum toxin from the circulating blood of rhesus monkeys. US Army Edgewood Arsenal: CRDL 2-38 Technical Memorandum.
128. Sugii, S., Ohishi, I., Sakaguchi, G. (1977a). Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect. Immun. 16: 910-14.
129. Sugii, S., Ohishi, I., Sakaguchi, G. (1977b). Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect. Immun. 17: 491-6.
130. Sugii, S., Ohishi, I., Sakaguchi, G. (1977c). Oral toxicities of Clostridium botulinum toxins. Jpn. J. Med. Sci. Biol. 30: 70-3.
131. Sugiyama H., Mills D.C. Intraintestinal toxin in infant mice challenged intragastrically with Clostridium botulinum spores. Infect. Immun 1978, 21:59-63.
132. Sugiyama H., DasGupta B., Yang K. Toxicity of purified botulinal toxin fed to mice. Proc. Soc. Exp. Biol. Med 1974, 147:589-591.
133. Varma J.K., Katsitadze G., Moiscrafishvili M., Zardiashvili T., Chokheli M., Tarkhashvili N., Jhorjholiani E., Chubinidze M., Kukhalashvili T., Khmaladze I., Chatkvetadze N., Imnadze P., Hoekstra M., Sobel J. Signs and symptoms predictive of death in patients with foodborne botulism -Republic of Georgia, 1980-2002. Clin. Infect. Dis 2004, 39:357-362.
134. Verderio C., Coco S., Rossetto O., Montecucco C., Matteoli M. Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. J. Neurochem 1999, 7:372-379.
135. Verderio C., Rossetto O., Grumelli C., Frassoni C., Montecucco C., Matteoli M. Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep 2006, 7:995-999.
136. Vincenzi F. Effect of botulinum toxin on autonomic nerves in a dually innervated tissue. Nature 1967, 213:394-395.
137. Weber J.T., Goodpasture H.C., Alexander H., Werner S.B., Hatheway C.L., Tauxe R.V. Wound botulism in a patient with a tooth abscess: case report and review. Clin. Infect. Dis 1993, 16:635-639.
138. Wein L.M., Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. PNAS 2005, 102:9984-9989.
139. Williams P.T., Poole M.J., Sahu A., Katos A.M., Anderson J., Hilmas C.J. Stability of botulinum neurotoxin. Soc. Neurosci. Abs 2007, 37th Annual Meeting, San Diego, CA, 727.15/NN27.
140. Yamasaki S., Baumeister A., Binz T., Blasi J., Link E., Cornille F., Roques B., Fykse E.M., Sudhof T.C., Jahn R., Niemann H. Cleavage of members of the synaptobrevin/VAMP family of types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 1994, 269:12764-12772.
141. Yndestad M., Loftsgard G. Susceptibility of mink to Clostridium botulinum type C toxin. Acta Vet. Scand 1970, 11:594-599.
142. Yokosawa N., Kurokawa Y., Tsuzuki K., Syuto B., Fujii N., Kimura K., Oguma K. Binding of Clostridium botulinum type C neurotoxin to different neuroblastoma cell lines. Infect. Immun 1989, 57:272-277.
143. Zacks S., SheffM. Biochemistry and mechanism of action of toxic proteins. US Army Edgewood Arsenal CRDL 1967, 1-8.